Synthetic and recombinant liraglutide show no significant difference in immunogenicity using novel PBMC-based testing
A novel PBMC-based assay found no significant immunogenicity difference between synthetic (generic) and recombinant (branded) liraglutide, validating synthetic peptide drugs while establishing a new method for detecting innate immune response-modulating impurities.
Quick Facts
What This Study Found
No significant immunogenicity difference: synthetic vs recombinant liraglutide. Novel PBMC-based IIRMI detection method established. Fresh PBMCs from multiple volunteers. TLR/NOD ligand challenge testing. FDA tentative approval of generic June 2024.
Key Numbers
How They Did This
PBMC-based assays with fresh cells from different volunteers. Liraglutide ± TLR/NOD ligands. Comparison of recent and aged products. Cytokine/chemokine measurement.
Why This Research Matters
As generic synthetic peptide drugs enter the market, ensuring equivalent immunogenicity is critical. This PBMC-based method detects unknown trace impurities that cell line-based systems might miss.
The Bigger Picture
This validates the broader trend toward synthetic peptide drug manufacturing. As more peptide generics enter the market, PBMC-based IIRMI testing could become a regulatory requirement.
What This Study Doesn't Tell Us
In vitro assay. PBMC response may not predict in vivo immunogenicity. Limited number of volunteers. Only liraglutide tested. Long-term immunogenicity not assessed.
Questions This Raises
- ?Should PBMC-based IIRMI testing be required for all synthetic peptide generics?
- ?Would the method detect impurities in other synthetic peptide drugs?
- ?Does the finding apply to all manufacturing variations of liraglutide?
Trust & Context
- Key Stat:
- Generic = branded for immunogenicity No significant immunogenicity difference between synthetic and recombinant liraglutide using a novel PBMC assay—validating generic peptide drug safety
- Evidence Grade:
- Novel methodology validation study. Important for regulatory science but limited to in vitro testing.
- Study Age:
- Published in 2025.
- Original Title:
- Assessment of innate immune response modulating impurities (IIRMI) in synthetic peptide drugs (liraglutide).
- Published In:
- Biochemical and biophysical research communications, 771, 151967 (2025)
- Authors:
- Tang, Yangming, Tang, Chao, Lu, Xiaojie, Xing, Xinhui
- Database ID:
- RPEP-13768
Evidence Hierarchy
Frequently Asked Questions
Are generic GLP-1 drugs as safe as brand-name versions?
This study provides reassurance: synthetic (generic) liraglutide showed no significant immunogenicity difference from recombinant (brand-name) liraglutide. Even though they are made differently—chemical synthesis vs biological production—the immune response to both was equivalent.
What is IIRMI testing?
IIRMI (innate immune response-modulating impurities) testing checks whether trace contaminants in a drug activate the immune system inappropriately. This study developed a new method using fresh human blood cells that can detect unknown impurities better than previous cell line-based tests.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13768APA
Tang, Yangming; Tang, Chao; Lu, Xiaojie; Xing, Xinhui. (2025). Assessment of innate immune response modulating impurities (IIRMI) in synthetic peptide drugs (liraglutide).. Biochemical and biophysical research communications, 771, 151967. https://doi.org/10.1016/j.bbrc.2025.151967
MLA
Tang, Yangming, et al. "Assessment of innate immune response modulating impurities (IIRMI) in synthetic peptide drugs (liraglutide).." Biochemical and biophysical research communications, 2025. https://doi.org/10.1016/j.bbrc.2025.151967
RethinkPeptides
RethinkPeptides Research Database. "Assessment of innate immune response modulating impurities (..." RPEP-13768. Retrieved from https://rethinkpeptides.com/research/tang-2025-assessment-of-innate-immune
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.